Plasma protein and lipoprotein distribution of clozapine

被引:25
作者
Procyshyn, RM [1 ]
Kennedy, NB [1 ]
Marriage, S [1 ]
Wasan, KM [1 ]
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Div Pharmaceut & Biopharmaceut, Vancouver, BC V6T 1Z3, Canada
关键词
D O I
10.1176/appi.ajp.158.987.949
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The authors' goal was to determine what effect dyslipidemia has on clozapine's plasma distribution. Method: [H-3]Clozapine plus cold clozapine (335 ng/ml) were incubated in plasma samples with varying total cholesterol, lipoprotein cholesterol, and triglyceride concentrations. Following incubation, the plasma was separated into its lipoprotein and lipoprotein-deficient fractions by density gradient ultracentrifugation and clozapine distribution was determined. Results: Compared with the plasma standard, significantly more clozapine was recovered in the very-low-density lipoprotein fraction, which contained elevated total cholesterol and triglycerides. Correlation analysis revealed a positive correlation between total plasma triglyceride concentration and clozapine recovery in this fraction. Conclusions: In plasma samples with elevated triglycerides, clozapine shifts from the lipoprotein-deficient fraction to the very-low-density lipoprotein fraction. This redistribution of clozapine may affect the pharmacological activity of clozapine.
引用
收藏
页码:949 / 951
页数:3
相关论文
共 23 条
[1]   INTERACTION OF PLASMA-PROTEINS AND LIPOPROTEINS WITH AMPHOTERICIN-B [J].
BRAJTBURG, J ;
ELBERG, S ;
BOLARD, J ;
KOBAYASHI, GS ;
LEVY, RA ;
OSTLUND, RE ;
SCHLESSINGER, D ;
MEDOFF, G .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (06) :986-997
[2]  
BRUNNER LJ, 1988, RES COMMUN CHEM PATH, V59, P339
[3]  
CLAGHORN J, 1987, J CLIN PSYCHOPHARM, V7, P377
[4]  
de la Chapelle A, 1977, Hum Genet, V37, P183
[5]  
Dursun SM, 1999, J PSYCHIATR NEUROSCI, V24, P453
[6]  
Gaulin BD, 1999, AM J PSYCHIAT, V156, P1270
[7]   Serum triglyceride levels in patients treated with clozapine [J].
Ghaeli, P ;
Dufresne, RL .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (17) :2079-2081
[8]  
GRIFFITH RW, 1975, LANCET, V2, P657
[9]   Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study [J].
Henderson, DC ;
Cagliero, E ;
Gray, C ;
Nasrallah, RA ;
Hayden, DL ;
Schoenfeld, DA ;
Goff, DC .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (06) :975-981
[10]   AGRANULOCYTOSIS DURING TREATMENT WITH CLOZAPINE [J].
IDANPAANHEIKKILA, J ;
ALHAVA, E ;
OLKINUORA, M ;
PALVA, IP .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (03) :193-198